Poland· PL-100334324
Viekirax
A ombitasvir, paritaprevir and ritonavir product containing ombitasvirum + paritaprevirum + ritonavirum, registered in Poland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 6 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ombitasvir, paritaprevir and ritonavir is registered in 6 of 19 countries.
Countries holding a registration under ATC J05AP53 (ombitasvir, paritaprevir and ritonavir), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Ombitasvir, paritaprevir and ritonavir · ATC J05AP53
6 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Polandprice
- Spainprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Ombitasvirum + Paritaprevirum + Ritonavirum
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Poland (PL)
- ATC code
- J05AP53
- ATC class
- Ombitasvir, paritaprevir and ritonavir
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08054083006888
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ombitasvir, paritaprevir and ritonavir in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ddef9012-ada6-4568-935f-9e6fa40980cc GET /v1/drugs/ddef9012-ada6-4568-935f-9e6fa40980cc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "12,5 mg + 75 mg + 50 mg",
"packaging": "08054083006888 ¦ Rpz ¦ EU/1/14/982/001 ¦ 106215\n56 tabl.",
"substance": "Ombitasvirum 12.5 mg + Paritaprevirum 75 mg + Ritonavirum 50 mg",
"common_name": "Ombitasvirum + Paritaprevirum + Ritonavirum",
"pl_product_id": "100334324",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": "2024-09-25"
}See everything about ombitasvir, paritaprevir and ritonavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.